Compass Pathways awards U.S. grants to five organizations developing post-approval COMP360 provider training programs

Compass Pathways announced five U.S. grant recipients selected through a competitive process to develop training programs for healthcare providers involved in delivering psychedelic treatments such as COMP360 psilocybin. The number of awards exceeded the company’s planned three because of the strength of the applicant pool. The programs are intended to provide foundational education about psychedelics and prepare providers to support patients receiving COMP360 if the treatment is approved and reaches commercial launch. The supplied description identifies the recipients’ expertise and proven experience as selection criteria, but does not provide their names, the grant amounts, or further details about the training curricula or approval timeline.